Baillie Gifford & Co’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.7M | Sell |
1,071,584
-49,690
| -4% | -$621K | 0.01% | 204 |
|
|
2025
Q4 | $14.5M | Sell |
1,121,274
-2,757
| -0.2% | -$35.4K | 0.01% | 204 |
|
|
2025
Q3 | $14.5M | Sell |
1,124,031
-4,621
| -0.4% | -$61.7K | 0.01% | 209 |
|
|
2025
Q2 | $20.1M | Sell |
1,128,652
-8,328
| -0.7% | -$145K | 0.02% | 189 |
|
|
2025
Q1 | $20.3M | Sell |
1,136,980
-24,330
| -2% | -$553K | 0.02% | 179 |
|
|
2024
Q4 | $34.6M | Sell |
1,161,310
-498,004
| -30% | -$10.5M | 0.03% | 161 |
|
|
2024
Q3 | $25.9M | Sell |
1,659,314
-28,207
| -2% | -$511K | 0.02% | 169 |
|
|
2024
Q2 | $28.9M | Sell |
1,687,521
-302,854
| -15% | -$5.33M | 0.02% | 163 |
|
|
2024
Q1 | $31.1M | Sell |
1,990,375
-2,849,766
| -59% | -$41.9M | 0.02% | 170 |
|
|
2023
Q4 | $72.3M | Sell |
4,840,141
-1,974,073
| -29% | -$26.4M | 0.06% | 139 |
|
|
2023
Q3 | $110M | Sell |
6,814,214
-1,876,250
| -22% | -$54.1M | 0.1% | 120 |
|
|
2023
Q2 | $361M | Buy |
8,690,464
+86,963
| +1% | +$5.4M | 0.31% | 76 |
|
|
2023
Q1 | $517M | Sell |
8,603,501
-260,341
| -3% | -$20.8M | 0.47% | 55 |
|
|
2022
Q4 | $650M | Sell |
8,863,842
-50,349
| -0.6% | -$3.79M | 0.68% | 39 |
|
|
2022
Q3 | $677M | Sell |
8,914,191
-202,039
| -2% | -$15.8M | 0.7% | 40 |
|
|
2022
Q2 | $634M | Sell |
9,116,230
-224,615
| -2% | -$16.9M | 0.65% | 42 |
|
|
2022
Q1 | $774M | Sell |
9,340,845
-274,323
| -3% | -$20.2M | 0.54% | 49 |
|
|
2021
Q4 | $722M | Buy |
9,615,168
+245,463
| +3% | +$24.6M | 0.4% | 67 |
|
|
2021
Q3 | $1.09B | Buy |
9,369,705
+68,624
| +0.7% | +$10.4M | 0.57% | 47 |
|
|
2021
Q2 | $2.06B | Buy |
9,301,081
+437,149
| +5% | +$85M | 1.01% | 25 |
|
|
2021
Q1 | $1.17B | Buy |
8,863,932
+602,857
| +7% | +$95.4M | 0.66% | 40 |
|
|
2020
Q4 | $1.43B | Buy |
8,261,075
+136,430
| +2% | +$18.7M | 0.8% | 32 |
|
|
2020
Q3 | $904M | Buy |
8,124,645
+220,925
| +3% | +$17.7M | 0.62% | 37 |
|
|
2020
Q2 | $469M | Buy |
7,903,720
+167,102
| +2% | +$11M | 0.36% | 53 |
|
|
2020
Q1 | $521M | Sell |
7,736,618
-272,364
| -3% | -$21.5M | 0.56% | 36 |
|
|
2019
Q4 | $675M | Sell |
8,008,982
-644,636
| -7% | -$52M | 0.65% | 32 |
|
|
2019
Q3 | $647M | Sell |
8,653,618
-175,831
| -2% | -$14.1M | 0.74% | 32 |
|
|
2019
Q2 | $558M | Buy |
8,829,449
+789,924
| +10% | +$40M | 0.59% | 41 |
|
|
2019
Q1 | $387M | Buy |
8,039,525
+3,541,001
| +79% | +$170M | 0.42% | 58 |
|
|
2018
Q4 | $151M | Buy |
4,498,524
+971,424
| +28% | +$35.5M | 0.2% | 82 |
|
|
2018
Q3 | $185M | Buy |
3,527,100
+433,705
| +14% | +$17.3M | 0.2% | 81 |
|
|
2018
Q2 | $96.8M | Buy |
3,093,395
+343,756
| +13% | +$9.56M | 0.1% | 90 |
|
|
2018
Q1 | $59.9M | Buy |
2,749,639
+2,145,522
| +355% | +$46.1M | 0.07% | 100 |
|
|
2017
Q4 | $12.2M | Buy |
+604,117
| New | +$11.6M | 0.02% | 160 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Baillie Gifford & Co's NVCR Position: Q1 2026 in Review
Baillie Gifford & Co reduced its NovoCure (NVCR) stake by 4.4% in Q1 2026, selling an estimated $621K and leaving 1,071,584 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #204.
Baillie Gifford & Co first reported a position in NVCR in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.06B in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Baillie Gifford & Co held 1,071,584 shares of NovoCure worth $11.7M as of Q1 2026.
- Baillie Gifford & Co sold 49,690 NovoCure shares in Q1 2026, an estimated $621K.
- NovoCure made up 0.01% of Baillie Gifford & Co's portfolio in Q1 2026, its #204 holding.
- Baillie Gifford & Co first reported a position in NovoCure in Q4 2017 and has held it in 34 quarters since.
- Baillie Gifford & Co's NovoCure position peaked at $2.06B in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Baillie Gifford & Co's 13F filing for Q1 2026, filed 8 May 2026.